Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Clin Rheumatol

Search In Journal Title:

Abbravation: Clinical Rheumatology

Search In Journal Abbravation:

Publisher

Springer London

Search In Publisher:

DOI

10.1002/ar.22739

Search In DOI:

ISSN

1434-9949

Search In ISSN:
Search In Title Of Papers:

High rate of disease remission in moderate rheumat

Authors: Florenzo Iannone Elisa Gremese Gaia Gallo Piercarlo SarziPuttini Costantino Botsios Francesco Trotta Stefania Gasperini Mauro Galeazzi Silvano Adami Fabrizio Cantini Marco Sebastiani Roberto Gorla Antonio Marchesoni AnnaRita Giardina Rosario Foti Angiola Mele Eleonora Bruschi Gianluca Bagnato Gian Luca Erre Giovanni Lapadula on behalf of GISEA Gruppo Italiano Studio Early Arthritis
Publish Date: 2013/08/18
Volume: 33, Issue: 1, Pages: 31-37
PDF Link

Abstract

The aim of this study was to evaluate the clinical outcomes of etanercept in rheumatoid arthritis RA patients with moderate or severe disease activity We analyzed data from the Italian biologics register Gruppo Italiano Studio Early Arthritides GISEA to investigate the rate of disease remission and functional improvement based on the 28Joint Disease Activity Score DAS28 and the Health Assessment Questionnaire HAQ score in RA patients with moderate or severe disease activity beginning etanercept therapy Disease was defined as severe HRA with DAS28 ≥51 and moderate MRA with DAS28 ≥32 to 51 at baseline Patients were considered in remission if DAS28 was ≤26 and HAQ ≤05 defined normal function We enrolled 953 RA patients 320 with MRA and 633 HRA Age and disease duration were similar in the two cohorts but HRA patients had significantly more comorbidities p  001 and took significantly more diseasemodifying antirheumatic drugs p  0001 than MRA patients After 1 year the percentage of patients achieving disease remission and normal function DAS28 ≤26 plus HAQ ≤05 was higher in MRA 214  than in HRA patients 148  p = 0007 regardless of the disease duration Additionally female gender p = 0006 and HRA class p = 0002 negatively predicted disease remission at 1 year However the drug survival rate did not differ between the two subsets This study confirms that etanercept was effective in the treatment of active RA but best response in terms of disease remission and normal function ability was greater and easier to attain in MRA patients These findings may aid clinicians to choose the best strategy to treat RAGruppo Italiano di Studio sulle Early Arthritides GISEA Crescenzio Scioscia Anna Laura Fedele Gianfranco Ferraccioli Fabiola Atzeni Sara Bongiovanni Leonardo Punzi Livio Bernardi Valentina Bagnari Marcello Govoni Walter Grassi Fausto Salaffi Stefania Manganelli Elena Frati Antonio Carletto Cristian Caimmi Alice Palloni Laura Niccoli Clodoveo Ferri Ennio Giulio Favalli Giovanni Triolo Marcella Di Gangi

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima–media in patients with systemic autoimmune diseases
  2. The virtuoso foot
  3. Responsiveness of the DASH score in surgically treated basal joint arthritis of the thumb: preliminary results
  4. RAPID3 scores and hand outcome measurements in RA patients: a preliminary study
  5. Bone mineral density in children with familial Mediterranean fever
  6. Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1
  7. Risk factors in transient osteoporosis: a retrospective study on 23 cases
  8. Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study
  9. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement
  10. The autonomic nervous system in systemic sclerosis. A review
  11. Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay
  12. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan
  13. Rheumatoid arthritis: should we shift the focus from “Treat to Target” to “Treat to Work?”
  14. Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis
  15. Severe deficiency of 25-hydroxyvitamin D 3 (25-OH-D 3 ) is associated with high disease activity of rheumatoid arthritis
  16. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren’s syndrome
  17. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)
  18. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared
  19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge
  20. Group visits for rheumatoid arthritis patients: a pilot study
  21. Identification of transcription regulatory relationships in rheumatoid arthritis and osteoarthritis
  22. The impact of current health-related quality of life on future health outlook in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)
  23. Two cases demonstrating thalidomide’s efficacy in refractory lupus nephritis
  24. Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic
  25. The challenge of profound hypoglycorrhachia: two cases of sarcoidosis and review of the literature
  26. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases
  27. Relationship of Q angle and joint hypermobility and Q angle values in different positions
  28. Osteoarthritis of the hip or knee: which coexisting disorders are disabling?
  29. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels
  30. T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet’s disease
  31. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab
  32. Oxidative status in rheumatoid arthritis
  33. Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey
  34. Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis
  35. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature
  36. Vitamin D and systemic lupus erythematosus: state of the art
  37. Challenges and opportunities for diagnosis and treatment of rheumatoid arthritis in Latin America
  38. Clostridium difficile : an under-recognized cause of reactive arthritis?
  39. Prevalence of rheumatic diseases in Raramuri people in Chihuahua, Mexico: a community-based study
  40. Clinical utility of magnetic resonance angiography (MRA) in the diagnosis and treatment of Takayasu’s arteritis
  41. A systematic review of homoeopathy for the treatment of fibromyalgia
  42. Do hip OA patients referred to orthopedic surgeons by general practitioners and rheumatologists differ?
  43. The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus
  44. Antistreptococcal Response is Exaggerated in Children with Familial Mediterranean Fever
  45. Beware of the biologicals—hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951–2010)
  46. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate
  47. QT dispersion in uncomplicated familial Mediterranean fever
  48. Ultrasonographic evaluation of the muscle architecture in patients with systemic lupus erythematosus
  49. Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin
  50. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis
  51. Autonomic dysfunction in psoriatic arthritis
  52. Exercise therapy for patients with diffuse idiopathic skeletal hyperostosis
  53. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients
  54. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis
  55. Increased expression of IL - 28RA mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
  56. Contrast-enhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response
  57. Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus
  58. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome
  59. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects
  60. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis
  61. Serum galectin-3 level in systemic sclerosis
  62. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema
  63. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  64. Familial Mediterranean fever responds well to infliximab: single case experience
  65. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  66. The role of PET/CT in Cogan’s syndrome
  67. Treatment of osteoporosis in renal insufficiency
  68. STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population
Search Result: